MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase 1
Completed
Conditions
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: Total Body Irradiation (TBI)
Drug: Granulocyte colony-stimulating factor (G-CSF)
Drug: Phenytoin
Drug: Methotrexate
First Posted Date
2005-10-27
Last Posted Date
2017-09-27
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
147
Registration Number
NCT00245037
Locations
🇺🇸

Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 2
Terminated
Conditions
Kidney Cancer
First Posted Date
2005-10-21
Last Posted Date
2012-05-28
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
1
Registration Number
NCT00243009
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
B-cell Leukemia
Chronic Leukemia
Chronic Lymphocytic Leukemia (CLL)
Interventions
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Cytoxan
First Posted Date
2005-09-30
Last Posted Date
2014-10-06
Lead Sponsor
Steven E. Coutre
Target Recruit Count
25
Registration Number
NCT00230282
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

Phase 2
Conditions
De Novo Akute Myeloid Leukemia (AML)
Secondary Acute Myeloid Leukemia (AML)
Refractory Anemia With Excess of Blasts in Transformation
First Posted Date
2005-09-21
Last Posted Date
2005-11-18
Lead Sponsor
Hannover Medical School
Target Recruit Count
200
Registration Number
NCT00209833
Locations
🇩🇪

Hannover Medical School, Hannover, Germany

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Phase 3
Conditions
Lymphoma, Mantle-Cell
Interventions
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Fludarabine
Procedure: Rituximab maintenance
Drug: Vincristine
Drug: Prednisone
Drug: Interferon-alpha
Drug: pegylated formula Interferon-alpha 2b
Procedure: Interferon maintenance
First Posted Date
2005-09-21
Last Posted Date
2017-03-07
Lead Sponsor
European Mantle Cell Lymphoma Network
Target Recruit Count
570
Registration Number
NCT00209209
Locations
🇳🇱

HOVON - Dutch Haemato-Oncology Association (HOVON-Datacenter), Rotterdam, Netherlands

🇩🇰

Nordic Lymphoma Group, Copenhagen, Denmark

🇩🇪

German Low Grade Study Group (Glsg), Munich, Germany

and more 4 locations

Efficacy of G-CSF-Priming in Elderly AML Patients

Phase 4
Conditions
Acute Myeloid Leukemia
First Posted Date
2005-09-20
Last Posted Date
2005-10-26
Lead Sponsor
Johann Wolfgang Goethe University Hospital
Target Recruit Count
250
Registration Number
NCT00199147
Locations
🇩🇪

University Hospital, Medical Department II, Frankfurt, Germany

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

First Posted Date
2005-09-20
Last Posted Date
2022-08-18
Lead Sponsor
Goethe University
Target Recruit Count
1883
Registration Number
NCT00198991
Locations
🇩🇪

University of Frankfurt, Medical Dept. II, Frankfurt, Germany

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Phase 1
Completed
Conditions
Hematologic Malignancies
First Posted Date
2005-09-20
Last Posted Date
2014-05-29
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
61
Registration Number
NCT00202917
Locations
🇩🇪

Center for Marrow Transplantation, Essen, Germany

🇩🇪

University of Wuerzburg Medical Center, Wuerzburg, Germany

🇩🇪

Deutsche Klinik für Diagnostik, Wiesbaden, Germany

and more 4 locations

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Phase 4
Completed
Conditions
Adult Acute Lymphocytic Leukemia
First Posted Date
2005-09-20
Last Posted Date
2023-03-20
Lead Sponsor
Goethe University
Target Recruit Count
225
Registration Number
NCT00199056
Locations
🇩🇪

University Hospital, Medical Dept. II, Frankfurt, Germany

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2
Completed
Conditions
Non-Hodgkins Lymphoma
First Posted Date
2005-09-19
Last Posted Date
2010-12-30
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
40
Registration Number
NCT00193466
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy